Medical Digest & Congress Report

HPV-associated head and neck cancers - report from Danube Symposium

15 May 2024

Contributed by Lukas

Professor Thomas Hoffmann, Director of the Department of Otolaryngology and Head and Neck Surgery at the University of Ulm, raises awareness of the gr...

Breakthroughs and challenges in the treatment of head and neck cancer - report from Danube Symposium

15 May 2024

Contributed by Lukas

Dr. Robert Sifrer, Director of the Department of Otolaryngology and Head and Neck Surgery at the University of Ljubljana, believes that the most impor...

Featured Clinical Researches: acute coronary syndromes, atrial fibrillation related ablation procedures and aortic valve replacements - report from ACC2024

19 Apr 2024

Contributed by Lukas

Professor George D. Dangas chaired the Featured Clinical Research on Monday and shared his insights on the trials about acute coronary syndromes, atri...

Late-Breaking Clinical Trials on Cholesterol Management, Hypertension and Exercise - report from ACC2024

19 Apr 2024

Contributed by Lukas

Professor Andrew M. Kates shared his insights on Late-Breaking Clinical Trials II, presented during at ACC.24: - Zilebesiran In Combination With A Sta...

Late Breaking Clinical Trial on ACC - report from ACC2024

19 Apr 2024

Contributed by Lukas

Professor Athena Poppas shared his insights on the Late Breaking Clinical Trial sessions: - Effect Of Edetate Disodium Based Chelation Infusions On Ca...

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF and STEP-HFpEF DM randomised trials - report from ACC2024

18 Apr 2024

Contributed by Lukas

Professor Mikhail Kosiborod shared his insights onthe STEP-HFpEF and STEP-HFpEF DM randomised trials. Discussed studies: - Semaglutide versus placebo...

Late-Breaking Clinical Trials V - report from ACC2024

17 Apr 2024

Contributed by Lukas

ACC Immediate-Past President Edward T. A. Fry chaired the Late Breaking Clinical Trial V. and shared his insights on the trials: - Coronary Sinus Redu...

Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials IV - report from ACC2024

17 Apr 2024

Contributed by Lukas

Professor Kathryn L. Berlacher shared his insights on Late-Breaking Clinical Trials IV, presented during at ACC.24: - Outcomes After Technology Assist...

Late Breaking Clinical Trial on interventional cardiology - report from ACC2024

17 Apr 2024

Contributed by Lukas

Professor Douglas E. Drachman shared his insights on the Late Breaking Clinical Trial sessions about interventional cardiology trials which he co-mo...

Lerodalcibep reduces LDL cholesterol by over 50% in high-risk patients - report from ACC2024

16 Apr 2024

Contributed by Lukas

Professor Eric Quinton Klug shared his insights on the LIBerate-HR trial. Among patients at high or very high risk for a heart attack or stroke, the a...

PROACT: Do ACE Inhibitors Help Prevent Cardiotoxicity in Patients Treated For Breast Cancer or Lymphoma? - report from ACC2024

16 Apr 2024

Contributed by Lukas

David Austin, the study's lead author shared his insights on the PROACT trial. Patients who took the ACE inhibitor enalapril while undergoing canc...

ULTIMATE-DAPT: Most Patients With ACS Can Safely Stop Aspirin One Month Post PCI - report from ACC2024

12 Apr 2024

Contributed by Lukas

Professor Gregg W. Stone shared his insights on the ULTIMATE-DAPT study. Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT...

EMPACT-MI: Empagliflozin Post MI Does Not Lower Risk of First HF Hospitalization, Death - report from ACC2024

12 Apr 2024

Contributed by Lukas

Professor Javed Butler shared his insights on the EMPACT-MI study. The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization...

Outcomes After Technology Assisted Nonprescription Rosuvastatin Administration: The TACTiC Trial - report from ACC2024

12 Apr 2024

Contributed by Lukas

Professor Steven E. Nissen shared his insights on the TACTiC study, presented during a Late-Breaking Clinical Trial session at ACC.24. The study prove...

Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials - report from ACC2024

11 Apr 2024

Contributed by Lukas

ACC President B. Hadley Wilson shared his insights on Late-Breaking Clinical Trials I, presented during at ACC.24: - RELIEVE-HF: Does Impact of Inter...

Percutaneous Transvalvular Micro-axial Flow Pump in Infarct Related Cardiogenic Shock - report from ACC2024

11 Apr 2024

Contributed by Lukas

Professor Robert Roswell shared his insights on the DanGer Shock trial. Implantation of the Impella CP micro-axial flow pump in the hours after a hear...

Study Links E-Cigarette Use with Higher Risk of Heart Failure - report from ACC2024

11 Apr 2024

Contributed by Lukas

Dr. Yakubu Bene-Alhasan shared his insights on the large study that adds to growing body of evidence that vaping may harm the heart. People who use e-...

Overall Survival Results of KEYNOTE-564

05 Apr 2024

Contributed by Lukas

We asked Professor Stefan N. Symeonides, one of the authors of the KEYNOTE-564 study, about the trial and the new data presented on overall survival a...

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

12 Feb 2024

Contributed by Lukas

We asked Professor David F. McDermott, investigator of the KEYNOTE-564 study, about the trial and the new data presented on overall survival at ASCO G...

Follicular Lymphoma highlights of the ASH 2023 Congress

26 Jan 2024

Contributed by Lukas

Professor Carla Casulo summarizes the most important highlights in the field of Follicular Lymphoma treatment after the 65th American Society of Hemat...

Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia - report from ASH2023

21 Dec 2023

Contributed by Lukas

Professor on frontline treatment with targeted agents in patients with Chronic Lymphocytic Leukemia. Video: https://medicaldigest.org/scientific-conte...

Real-World Outcomes With Brexucabtagene Autoleucel - report from ASH2023

21 Dec 2023

Contributed by Lukas

Professor Swetha Kambhampati on Mantle Cell Lymphoma: Real-World Outcomes With Brexucabtagene Autoleucel. Video: https://medicaldigest.org/scientific-...

Ibrutinib-Venetoclax Combination Found Effective Against Mantle Cell Lymphoma - report from ASH2023

21 Dec 2023

Contributed by Lukas

Professor Michael Wang explains their findings that combining ibrutinib and venetoclax improves progression-free survival and remission rates in patie...

Present and future of Multiple Myeloma management - report from ASH2023

21 Dec 2023

Contributed by Lukas

Professor Xavier Leleu explains the present and future of Multiple Myeloma management, how new regiments, new treatments will change how we treat pati...

Highlights of the ASH 2023 Congress

21 Dec 2023

Contributed by Lukas

Professor Mikkael Sekeres summarizes the most important highlights that presented at the 65th American Society of Hematology Annual Meeting. Video: ht...

Chronic Myeloid Leukemia: Novel Therapeutic Approaches - report from ASH2023

20 Dec 2023

Contributed by Lukas

Professor Carmen Fava summarizes the therapeutic novelties of Chronic Myeloid Leukemia management at the 65th American Society of Hematology Annual Me...

Acute myeloid leukemia highlights of ASH 2023 Congress

20 Dec 2023

Contributed by Lukas

Professor Eunice S. Wang summarizes the most important highlights in the field of Acute Myeloid Leukemia treatment at the 65th American Society of Hem...

Chronic Myeloid Leukemia highlights of ASH 2023 Congress

20 Dec 2023

Contributed by Lukas

Professor Giuseppe Saglio summarizes the most important highlights in the field of Chronic Myeloid Leukemia treatment at the 65th American Society of ...

Multiple Myeloma highlights of ASH 2023 Congress

20 Dec 2023

Contributed by Lukas

Professor Andrzej Jakubowiak summarizes the most important highlights in the field of MultiplMyeloma treatment at the 65th American Society of Hematol...

Dramatically Worse Myeloma Outcomes in Real World vs. Trials - report from ASH2023

20 Dec 2023

Contributed by Lukas

Dr. Alissa Visram on the presented the data during 65th American Society of Hematology Annual Meeting. Patients with multiple myeloma who were treated...

State of the art ALL treatement in 2023 - report from ASH2023

19 Dec 2023

Contributed by Lukas

Professor Marlise R. Luskin summarizes the state of the art acute lymphoblastic leukemia treatement at the 65th American Society of Hematology Annual ...

Acute myeloid leukemia highlights of the ASH 2023 Congress

19 Dec 2023

Contributed by Lukas

Professor Agnieszka Wierzbowska summarizes the most important highlights in the field of acute myeloid leukemia treatment at the 65th American Society...

Diagnostic and Therapeutic Novelties of Multiple Myeloma Management at ASH2023

19 Dec 2023

Contributed by Lukas

Professor Enrique Ocio summarizes the diagnostic and therapeutic novelties of Multiple Myeloma management at the 65th American Society of Hematology A...

Non-Hodgkin Lymphoma highlights of the ASH 2023 Congress - report from ASH2023

19 Dec 2023

Contributed by Lukas

Professor Umberto Vitolo summarizes the most important highlights in the field of Non-Hodgkin Lymphoma treatment at the 65th American Society of Hemat...

Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone Outperforms VRd Alone for Multiple Myeloma - report from ASH2023

18 Dec 2023

Contributed by Lukas

Professor Pieter Sonneveld explains that newly diagnosed patients with multiple myeloma who received daratumumab along with the standard care regimen ...

Revumenib Found Effective Against High-Risk KMT2Ar Acute Leukemia - report from ASH2023

18 Dec 2023

Contributed by Lukas

Professor Ibrahim Aldoss explains that patients with relapsed or refractory acute leukemia with rearrangement in the lysine methyltransferase 2a gene,...

Auto-HCT Improves PFS, Relapse Rates in Relapsed LBCL Subset During Complete Response - report from ASH2023

15 Dec 2023

Contributed by Lukas

Professor Mazyar Shadman on the findings from a real-world, retrospective study that were presented during the 2023 ASH Annual Meeting: Autologous hem...

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL - report from ASH2023

15 Dec 2023

Contributed by Lukas

Professor Peter Hillmen on the combination of ibrutinib and venetoclax, at a duration determined by minimal residual disease, improved progression-fre...

Interpretable Artificial Intelligence Differentiates Prefibrotic Primary Myelofibrosis from Essential Thrombocythemia - report from ASH2023

13 Dec 2023

Contributed by Lukas

Professor Andrew Srisuwananukorn's research revealed that an AI-powered machine learning algorithm, when examining digital whole-slide images of d...

CD19-Targeted CAR-T Cells in Refractory Systemic Autoimmune Diseases - report from ASH2023

13 Dec 2023

Contributed by Lukas

Professor Fabien Mueller explains preliminary results from an early-stage study presented at the American Society of Hematology meeting over the weeke...

Medical Treatment of Renal Cell Carcinoma in 2023

04 Dec 2023

Contributed by Lukas

Professor Viktor Grünwald at ESMO 2023 had a lecture on prognostic factors of renal cell carcinoma and in a recent podcast analyzed the importance of...

Lung Cancer highlights of ESMO 2023 Congress

29 Nov 2023

Contributed by Lukas

Professor Luis Paz-Ares explains the most important novelties in the field of lung cancer treatement after ESMO 2023. - Early stage trails: ADAURA, AL...

State of art lipid-lowering treatment in 2023

23 Nov 2023

Contributed by Lukas

Professor Stephen Nicholls summarizes the state of art lipid lowering therapy after ESC 2023. Video: https://medicaldigest.org/scientific-contents/int...

The importance of intensive lipid lowering in CV risk reduction: the role of early combination treatment

23 Nov 2023

Contributed by Lukas

Professor Alberto Zambon explains the significance of intensive lipid lowering therapy in cardiovascular risk reduction after ESC 2023. He highlights ...

Lung cancer highlights of the ESMO 2023 Congress

10 Nov 2023

Contributed by Lukas

Professor Benjamin Besse shares his insight on novelties in lung cancer treatment presented at ESMO 2023 Congress. Topics mentioned are targeted thera...

Melanoma highlights of ESMO 2023 Congress

08 Nov 2023

Contributed by Lukas

Professor Karijn Suijkerbuijk shares with us some highlights from ESMO 2023 on Melanoma. On neoadjuvant treatments of cutaneous melanoma, a small but ...

RCC highlights of ESMO 2023 Congress

08 Nov 2023

Contributed by Lukas

Camillo Porta shares his thoughts about the most important novelties in RCC treatment. Studies such as: - Belzutifan/LITESPARK studies: LITESPARK-003 ...

Genitourinary cancer highlights of ESMO 2023 Congress

08 Nov 2023

Contributed by Lukas

Silke Gillessen explains the most important stories in GU cancers at ESMO 2023. Studies such as: - EV-302/KEYNOTE-A39 trial: Risk of death was reduced...

Breast Cancer highlights of the ESMO 2023 Congress

07 Nov 2023

Contributed by Lukas

Professor Hope Rugo shares her insights on the breast cancer highlights of #ESMO23 meeting, and also how they apply them in clinical practice. This wa...

Treatment of mRCC in real world settings - report from ESMO2023

06 Nov 2023

Contributed by Lukas

Professor Daniel Heng shares his thoughts on the developments of the last few years in the field of mRCC. Video: https://medicaldigest.org/scientific-...

Antibody-Drug Conjugate Boosts Survival in Recurrent/Metastatic Cervical Cancer - report from ESMO2023

06 Nov 2023

Contributed by Lukas

Professor Krishnansu Sujata Tewari explains the results from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with tisotumab v...

Data Shows Survival Benefits with Tisotumab Vedotin in Cervical Cancer - report from ESMO2023

03 Nov 2023

Contributed by Lukas

Professor Ignace B. Vergote explains the results from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with tisotumab vedotin ...

Late-breaking studies from ESMO 2023 - report from ESMO2023

03 Nov 2023

Contributed by Lukas

Professor Paweł Sobczuk shares his thoughts on five interesting studies presented during #ESMO23. These groundbreaking studies is form different tumo...

KEYNOTE-942 mRNA-Based vaccine and novel techniques in the field of melanoma - report from ESMO2023

03 Nov 2023

Contributed by Lukas

Professor Jeffrey Weber shares his thoughts on the novel techniques in the field of melanoma. Like 5-Year Efficacy and Biomarker Results from CheckMat...

Targeted Combination Wins in KRAS-Positive Metastatic Colorectal Cancer - report from ESMO2023

02 Nov 2023

Contributed by Lukas

Professor Filippo Pietrantonio discusses the influence of primary results from the phase 3 CodeBreak 300 trial of sotorasib plus panitumumab on KRAS G...

Better use of existing drugs increases cervical cancer survival and reduces recurrence - report from ESMO2023

02 Nov 2023

Contributed by Lukas

Professor Krishnansu Sujata Tewari explains the results from he INTERLACE phase 3 trial, assessed whether a short course of induction chemotherapy pri...

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer - report from ESMO2023

02 Nov 2023

Contributed by Lukas

Professor Mary McCormack explains the results from the GCIG INTERLACE trial presented in a Presidential Symposium at the ESMO Congress 2023. Phase III...

The CodeBreak 300 Trial in KRAS G12C-mutated mCRC - report from ESMO2023

01 Nov 2023

Contributed by Lukas

Professor Clara Montagut Viladot discusses the primary results from the phase 3 CodeBreak 300 trial of sotorasib plus panitumumab in KRAS G12C–mutat...

Survival Improved With Nivolumab Plus Chemo in Urothelial Carcinoma - report from ESMO2023

01 Nov 2023

Contributed by Lukas

Professor Michiel van der Heijden presented the results of CheckMate 901, a phase III trial evaluating the combination of nivolumab plus gemcitabine/c...

Amivantamab Plus Chemotherapy as New First-Line Standard of Care in EGFR Exon 20 Insertion-Mutated Advanced NSCLC - report from ESMO2023

01 Nov 2023

Contributed by Lukas

Professor Nicolas Girard explains primary efficacy results from the phase 3 PAPILLON trial of amivantamab plus chemotherapy in EGFR exon 20 insertion–...

Selpercatinib improves outcomes in RET-mutant medullary thyroid cancer - report from ESMO2023

31 Oct 2023

Contributed by Lukas

Professor Laura Locati highlights findings from phase 3 LIBRETTO-531 trial, that has demonstrated the superiority of selpercatinib, a highly selective...

PSMAfore Study Unveils Game-Changing Results for Prostate Cancer Treatment - report from ESMO2023

30 Oct 2023

Contributed by Lukas

Professor Oliver Sartor highlights findings from the phase 3 PSMAfore trial exploring 177Lu-PSMA-617 in patients with taxane-naive metastatic castrati...

Considerations of moderate asthma management - report from ERS2023

04 Oct 2023

Contributed by Lukas

Professor Giorgio Walter Canonica sharing his insights on moderate asthma treatment. The professor will give answers to questions such as: - According...

Heart Failure management in the post-COVID era - Lessons from the pandemic - report from ESC2023

13 Sep 2023

Contributed by Lukas

Professor Theresa McDonagh discusses how to deal with the legacy of COVID-19 for our patients and shares her advices. Video: https://medicaldigest.org...

Key points from the 2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - report from ESC2023

13 Sep 2023

Contributed by Lukas

Professor Marco Metra was the co-chairman of the update to the ESC Heart Failure guidelines of 2021. The update incorporate data from nearly a dozen n...

Prospective Meta-Analysis of SGLT2 Inhibitor Randomized Trials in COVID-19 - report from ESC2023

12 Sep 2023

Contributed by Lukas

Professor Mikhail Kosiborod explains the findings of the Meta-Analysis, shows SGLT2 inhibitors do not reduce 28-day mortality in hospitalized COVID-19...

Burden of Cardiovascular Disease in the European Union - report from ESC2023

12 Sep 2023

Contributed by Lukas

Professor Panos Vardas highlights the economic burden of cardiovascular diseases in the European Union. CVD cost the EU an estimated €282 billion in...

Highlights of ESC2023 Congress - Heart failure in focus - report from ESC2023

12 Sep 2023

Contributed by Lukas

Professor Carlos Aguiar discusses the highlights of the ESC2023 annual congress, shares his thougths on many great news, novelties that could be chang...

2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes - from the cardiologist's perspective - report from ESC2023

11 Sep 2023

Contributed by Lukas

Professor Nikolaus Marx, was the co-chairman of the new European Society of Cardiology Guidelines of the Management of Cardiovascular Disease in Patie...

Main headlines of 2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - report from ESC2023

11 Sep 2023

Contributed by Lukas

Professor Theresa McDonagh was the co-chair of the update to the ESC Heart Failure guidelines of 2021 which incorporates data from nearly a dozen new ...

STEP HFpEF: once-weekly semaglutide in people with HFpEF and obesity - report from ESC2023

11 Sep 2023

Contributed by Lukas

Professor Mikhail Kosiborod provides a summary of the STEP HFpEF trial, in which semaglutide improves heart failure-related symptoms and physical func...

When real-world data meet real patients' needs: how to optimally treat patients with chronic coronary syndromes in 2023? - report from ESC2023

11 Sep 2023

Contributed by Lukas

Professor Luis Henrique Gowdak share his thought how to treat patients optimally with chronic coronary syndromes in 2023. Video: https://medicaldigest...

OCT vs. IVUS vs. angiography guidance: a real-time updated network meta-analysis - report from ESC2023

07 Sep 2023

Contributed by Lukas

Professor Gregg Stone provides a summary from a real-time updated network meta-analysis comparing OCT, IVUS and Angiography guidance in percutaneous c...

2023 ESC Guidelines for the Management of Endocarditis - report from ESC2023

07 Sep 2023

Contributed by Lukas

Professor Michael A. Borger, was the co-chairman of the new European Society of Cardiology Guidelines for the Management of Endocarditis. The overarch...

DICTATE-AHF: Early Dapagliflozin Initiation in Acute Heart Failure - report from ESC2023

07 Sep 2023

Contributed by Lukas

Professor Zachary Cox provides a summary of the DICTATE-AHF trial which showed that in patients with ADHF requiring inpatient IV loop diuretic therapy...

HEART-FID: Ferric Carboxymaltose in Heart Failure with Iron Deficiency - report from ESC2023

07 Sep 2023

Contributed by Lukas

Professor Robert Mentz provides a summary of the HEART-FID trial. The study investigated the long-term safety and efficacy of supplementing heart fail...

BUDAPEST CRT Upgrade: Cardiac resynchronisation therapy upgrade in heart failure with right ventricular pacing - a multicentre, randomised, controlled trial - report from ESC2023

06 Sep 2023

Contributed by Lukas

Professor Bela Merkely provides a summary of the BUDAPEST CRT Upgrade trial. The randomized, multicenre study shows, that among patients with heart fa...

2023 ESC Guidelines for the Management of Acute Coronary Syndromes - report from ESC2023

06 Sep 2023

Contributed by Lukas

Professor Borja Ibanez co-chaired of the new 2023 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndromes. This is th...

2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes - from the diabetologist's perspective - report from ESC2023

06 Sep 2023

Contributed by Lukas

Professor Massimo Federici, was the co-chairman of the new European Society of Cardiology Guidelines of the Management of Cardiovascular Disease in ...

2023 ESC Guidelines for the Management of Cardiomyopathies - report from ESC2023

06 Sep 2023

Contributed by Lukas

Professor Juan Pablo Kaski co-chaired the brand new European Society of Cardiology Guidelines for the Management of Cardiomyopathies. This is the fi...

What is the optimal treatment of hypertension in diabetics? The ESH 2023 Hypertension Guidelines on Diabetes - report from ESH2023

18 Jul 2023

Contributed by Lukas

Professor Josep Redon shares his insights on the special issues the European Society of Hypertension Guidelines covers, focusing on the best treatment...

Diabetes trials on SGLT2 and GLP1 and their effects on hypertension - report from ESH2023

18 Jul 2023

Contributed by Lukas

Professor Peter Nilsson held a lecture on the cardiovascular effects of SGLT-2 inhibitors and GLP-1 agonists, the two new drug classes which revolutio...

The Rehabilitation of Beta-Blockers in the ESH Hypertension Guidelines - report from ESH2023

12 Jul 2023

Contributed by Lukas

Professor Sverre Erik Kjeldsen explains how the role of the beta-blockers changed a in the new ESH Hypertension guideline. Video: https://medicaldiges...

Hypertensive patients with diabetes: Are RAAS/Diuretic combinations the foundation of treatment? - report from ESH2023

12 Jul 2023

Contributed by Lukas

Professor Otavio Berwanger shares his insight related to the management of patients with hypertension and diabetes. Video: https://medicaldigest.org/s...

Managing Hypertension in Real Practice: the New ESH2023 Hypertension Guidelines - report from ESH2023

12 Jul 2023

Contributed by Lukas

Professor Gianfranco Parati shares his insight on the new ESH Hypertension guidelines, how we should better manage hypertension in our patients. Video...

Hyperuricemia in hypertensive patients - report from ESH2023

12 Jul 2023

Contributed by Lukas

Professor Claudio Borghi on the elevated uric acid levels in hypertension. Which patient should be treated, when and how? Video: https://medicaldigest...

Hypertension in women - an underrecognized issue- report from ESH2023

10 Jul 2023

Contributed by Lukas

Professor Renata Cifkova was responsible in the new ESH Hypertension guideline for the topic of hypertension in women. In the interview, she explained...

What has changed in the new ESH Hypertension Guidelines? - report from ESH2023

10 Jul 2023

Contributed by Lukas

Professor Bryan Williams was the driving force behind the 2018 ESH/ESC Hypertension guideline. Many points - including the algorithm for drug therapy ...

When hypertension and dyslipidemia co-exist: How to decrease CV risk? - report from ESH2023

10 Jul 2023

Contributed by Lukas

Dr. Vitoria Cunha explains what is the relationship and effect of hypertension and dyslipidemia on each other? Is it recommended to treat the two risk...

Hypertensive patients with heart disease: What should be the preferred combination? - report from ESH2023

10 Jul 2023

Contributed by Lukas

Professor Konstantinos Tsioufis highlights an important aspect of the new ESH Hypertension guideline: hypertension and cardiac diseases. How these are...

Where is the role of triple combination in the management of hypertension? - report from ESH2023

07 Jul 2023

Contributed by Lukas

Professor Reinhold Kreutz shares his insights about the antihypertensive triple fixed combinations.What pathophysiological bases justify the use of tr...

The development of hypertension guidelines - report from ESH2023

07 Jul 2023

Contributed by Lukas

Professor Neil Poulter share his insights on the development of guidelines and the treatment in general in the last 15 years, and the practical applic...

”Ten Commandments” of Single Pill Combination Treatment in Hypertension - report from ESH2023

05 Jul 2023

Contributed by Lukas

Professor Krzysztof Narkiewicz Explains his Take on Single Pill Combination Treatment in Hypertension. Video: https://medicaldigest.org/scientific-con...

Beta-blockers in managing arterial hypertension - why, when and to whom? - report from ESH2023

05 Jul 2023

Contributed by Lukas

Professor Felix Mahfoud explains the place of beta-blockers in the new ESH guideline, and in combination he recommends them even in the first line. Vi...

Beyond the algorithm: What combination to choose in hypertension treatment? - report from ESH2023

05 Jul 2023

Contributed by Lukas

Professor Martin Strauss explains the preferred treatment of hypertension with a preferred RAAS blockade inhibitors. What kind of pill combination to ...

Antihypertensive Drugs and Treatment Algorithms in the ESH2023 Hypertension Guidelines - report from ESH2023

05 Jul 2023

Contributed by Lukas

Professor Michel Burnier presented the general aspects of the new European Society of Hypertension guidelines at ESH 2023. What are the major changes?...

Hypertension and kidney - the intricate relationship - report from ESH2023

05 Jul 2023

Contributed by Lukas

Professor Pantelis Sarafidis shared his insights on kidney disease and hypertension, and what the new ESH guidelines said about the management the hyp...

Hot questions on blood pressure measurement in clinical practice - report from ESH2023

05 Jul 2023

Contributed by Lukas

Professor Paolo Palatini chaired a very interesting session at the ESH 2023 about the hot questions on blood pressure measurement. - How to best perf...

Significant LDL Cholesterol Reductions With ANGPTL3 siRNA in homozygous familial hypercholesterolaemia - report from EAS2023

19 Jun 2023

Contributed by Lukas

Professor Frederick Raal about an interim analysis of a phase 2 study demonstrates that the RNAi therapeutic ARO-ANG3 reduces LDL-c and ApoB in patien...

HER2 treatment landscape 2023 - report from ESMO BC 2023

05 Jun 2023

Contributed by Lukas

Professor Javier Cortés, Head of the International Breast Cancer Center in Barcelona, Spain explains the HER2 treatment landscape in 2023. The interv...